本文選題：肝癌 + 射頻消融術��； 參考：《腫瘤防治研究》2017年12期

【摘要】：目的比較射頻消融術(radiofrequency ablation,RFA)和立體定向放射治療(stereotactic body radiotherapy,SBRT)對原發(fā)性小肝癌患者的臨床療效及安全性。方法回顧性分析2013年6月至2015年3月河南省腫瘤醫(yī)院收治的肝癌患者86例,RFA組49例、SBRT組37例。比較兩組近期療效、不良反應發(fā)生情況以及隨訪2年總生存率和腫瘤病灶局部控制率。結果兩組患者基線資料差異無統(tǒng)計學意義。RFA組患者近期治療有效率為81.9%,疾病控制率達到95.9%;SBRT組近期有效率為83.8%,疾病控制率達到91.9%,兩組差異無統(tǒng)計學意義。兩組治療后均未出現(xiàn)嚴重并發(fā)癥。RFA組治療后1年和2年總生存率為95.9%和85.7%,SBRT組分別為91.9%和83.8%,兩組差異無統(tǒng)計學意義。結論 RFA介入治療與SBRT治療對腫瘤直徑≤5 cm的單發(fā)肝癌患者具有較好的近期和遠期療效,對于不適合手術切除的肝癌患者,立體定向放療可以作為射頻消融術治療的一種替代手段。
[Abstract]:Objective to compare the clinical efficacy and safety of radiofrequency ablation (RFA) and stereotactic body radiotherapySBRT (stereotactic body radiotherapySBRT) in patients with small hepatocellular carcinoma (HCC). Methods from June 2013 to March 2015, 86 patients with liver cancer treated in Henan Cancer Hospital were analyzed retrospectively. There were 49 patients in RFA group and 37 patients in SBRT group. The short-term curative effect, adverse reaction, 2-year survival rate and local control rate of tumor were compared between the two groups. Results there was no significant difference in baseline data between the two groups. The effective rate of short-term treatment was 81.9 in RFA group, 83.8 in SBRT group and 91.9 in SBRT group. There was no significant difference between the two groups. There were no serious complications in both groups. The 1 and 2 year overall survival rates of RFA group were 91.9% and 83.8%, respectively. There was no significant difference between the two groups. Conclusion RFA interventional therapy and SBRT therapy have good short-term and long-term results in patients with single HCC with tumor diameter 鈮，

本文編號：1808732